Cystic Fibrosis Foundation issued three clinical trial alerts on 01/19/2023: two enrolling, one results
Status: Enrolling
Description: This study will evaluate the safety and tolerability of VX-522, an investigational gene therapy, in adults with CF whose mutations are not responsive to CFTR modulator therapy.
Age: 18 Years to 65 Years
Mutation: No Copies F508del
Fev1% Predicted: 40% or greater
Number of Visits: 8
Length of Participation: 6 months
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05668741
Status: Enrolling
Description: This study will evaluate the efficacy and safety of the study drug ARV-1801, an oral drug intended to treat infections in the lung. The study also will evaluate how the body process the drug.
Age: 12 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 5
Length of Participation: 28 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05641298
Status: Completed with results
Description: This study evaluated the effects and safety of stopping inhaled hypertonic saline or dornase alfa (Pulmozyme®) in teens and adults with CF who are also taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (Trikafta®).
Age: 12 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 60% or greater
Number of Visits: 4
Length of Participation: 10 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04378153